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A b s t r a c t  
The aim of the research was to study the stability, release profile, pharmacokinetic and 
biodistribution properties of zidovudine (AZT)-solidified reverse micellar microparticulate. Lipid 
matrices formulated with Phospholipon® 90H and goat fat at ratios of 1:1, 2:1, 3:1 and 2:3 were 
used to prepare AZT-loaded SLM by melt dispersion followed by lyophilization. In vitro release 
studies of the drug were carried out using a sequential drug release method in both SGF (pH 1.2) 
and SIF (pH 7.2) while the in vivo drug release studies were carried out using Wistar albino rats. The 
result of our findings showed that the drug is compatibility with the lipid matrix with the 1:1 showing 
the most stable microparticle preparation which was then optimized. The formulations showed a 
concentration dependent increase in their concentration maximum (Cmax) with values of 116.05 
øg/ml, 124.21 øg/ml, 128.95 øg/ml, 138.95 øg/ml and time to reach maximum concentration (Tmax) 
values of 5h, 8 h, 8 h, and 5 h for batches B1, B2, B3 and B4 containing 1 %, 2 %, 3 % and 5 % of 
AZT respectively. The area under curves (AUCs) of the microparticles formulated showed that the 
bioavailabilities of the microparticles were comparable to that of the conventional release tablet. The 
biodistribution studies of the microparticles in rats showed highest concentration of the drug in the 
liver with the least in the brain and higher biodistribution in various organs than pure AZT. The data 
suggested that SLM could be a promising drug delivery system to improve on the shortcomings of 
pharmacokinetics and bio-distribution properties of conventional AZT tablets like fluctuation in blood 
levels of the drug.  
Keywords: solidified lipid microparticle (SLM), lipid matrix, Phospholipon® 90H, human 
immunodeficiency virus, highly active antiretroviral therapy. 
 
Introduction 
Tens of millions of people are currently infected by human 
immunodeficiency virus-1 (HIV-1) and millions of new infections 
occur each year [1-6]. HIV-1 infection leads to acquired 
immunodeficiency syndrome (AIDS) as a result of low levels of 
CD4+ T cells that are directly killed by human immunodeficiency 
virus (HIV) and/or by apoptosis of infected CD4+ T cells and 
indirect killing by CD8 cytotoxic T-lymphocytes. Zidovudine (AZT), 
a nucleoside reverse transcriptase inhibitor (NRTI), is the first 
antiretroviral drug that has proven effective in preventing vertical 
transmission of HIV, thus reducing mother-to-child HIV 
transmission (MTCT) from 25 % to 8 % in the absence of 
breastfeeding [7]. Conventional AZT tablets have systemic 
availability of 65 % (range 52 to 75 %), while its concentration is 
maintained within the therapeutic range of 106.9-1069 øg/L. It is 
30-38 % protein bound and is metabolized in the liver with a half-
life of 3-5 h and renally excreted. According to Vanhove et al. [8] 
using parametric model; the mean pharmacokinetic parameters, 
the Tmax, Cmax, AUC, T1/2 of AZT were 1.29 h, 347 ng/ml, 1260 
ng h/ml, 0.76 h for AZT respectively. Modern treatment regimens 
typically use lower dosages of zidovudine (e.g. 300 mg) two times 
a day. As of 1996, AZT, like other antiretroviral drugs, is almost 
always used as part of highly active antiretroviral therapy (HAART). 
That is, it is combined with other drugs in order to prevent mutation 
of HIV into an AZT-resistant form [9, 10]. Like most other drugs, 
this drug had its own share of side effects. Also, the necessity of 
taking the drug daily poses a problem of compliance, since the 
conventional 300-mg tablet dosage form is taken twice daily. 
Despite the in vitro efficacy of antiretroviral drugs, AZT inclusive, 
pharmacological treatment is compromised by its inherent physico-
chemical properties and limitations in bio-distribution and cellular 
uptake leading to impediment in the effective drug bioavailability 
owing to restricted transport across the blood-brain barrier (BBB) 
as human immuno viral reservoir in the central nervous system 
(CNS) is high. Protease inhibitors have limited ability to reach the 
CNS, with majority of this class of drugs not detected in human 
cerebrospinal fluid (CSF). Body compartments with blood‐tissue 
barriers prevent drug penetration, thus preventing the eradication 
of latent viral pools. Active transport mechanisms involving proteins 
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of the ATP‐binding cassette (P‐glycoprotein) that are present, for 
example, in central nervous system (CNS) prevent the penetration 
of anti‐HIV drugs into the brain [11]. However, many promising 
anti-retroviral (ARV) agents are unfortunately compromised by 
disadvantageous physicochemical properties which lead to poor 
biodistribution and insufficient cellular uptake [12, 13]. Owing to the 
shortcomings in pharmacokinetic data (very short half due to first-
pass metabolism and fast renal excretion) and variable bio-
distribution (poor BBB transport and cerebrospinal fluid barrier) 
there is need to formulate these drugs in novel drug delivery 
system like solid lipid microparticles (SLM)s.  
The very slow progress in the efficacy of the treatment of severe 
diseases has suggested a growing need for a multidisciplinary 
approach to the delivery of therapeutics to targets in tissues [14]. 
There is growing interest and investment in the use of lipid-based 
systems in drug discovery and product development to effectively 
overcome physical and biological barriers related to poor aqueous 
solubility and stability, membrane permeability, drug efflux and 
availability [15]. Solid lipids have the advantage of providing more 
flexibility in controlling the drug release and protecting the 
encapsulated ingredients from chemical degradation. Also, they 
allow for the incorporation of hydrophilic or hydrophobic drugs [16, 
17]. SLMs can avoid use of organic solvent, non-toxicity of the 
carrier system, chemical and physical storage stability for both the 
carrier and the drug, low cost of ingredients, ease in the 
preparation and high scale-up potential [18-20]. Controlled drug 
delivery technology represents one of the frontier areas of science 
which involves a multidisciplinary scientific approach, contributing 
to human health care. The need for non-invasive drug delivery 
systems is a result of patientÊs non compliance and poor 
acceptability of the existing delivery regimens, limited market size 
for drug companies and drug users, coupled with a high cost of 
disease management. It has been proved in vitro that SLMs can 
reasonably be considered as a suitable carrier to provide a 
sustained release to the incorporated substance. This work was 
geared towards utilizing these unique properties of lipids in 
formulating a sustained release form of zidovudine to be delivered 
once daily.  
Thus, the aim of this study was to evaluate the pharmacokinetics 
and biodistribution of zidovudine-loaded SLMs in immune-
compromised rats in comparison with the commercially available 
immediate release zidovudine tablets. Results of the 
pharmacokinetics and bio-distribution of sustained-release SLMs 
containing AZT in immune-compromised rats were compared with 
the pharmacokinetics and bio-distribution properties of 
conventional oral tablets of AZT. 
Material and Methods  
Materials 
The materials used were Phospholipon® 90H, a hydrogenated 
lecithin (Phospholipid GmbH, Köln, Germany), thiomersal, 
Poloxamer 188 (a non-ionic tri-block copolymers composed of a 
central hydrophobic chain of polyoxypropylene flanked by two 
hydrophilic chains of polyoxythylene  (BASF, Germany), zidovudine 
(a gift from Fidson Healthcare, Nigeria), hydrochloric acid, sodium 
chloride, sodium hydroxide, monobasic sodium phosphate (Merck, 
Darmstadt, Germany),  cyclophosphamide (Oncomide®, 
Khandelwal, India) and distilled water (Lion Water, University of 
Nigeria, Nsukka). All other reagents and solvents were of analytical 
grade and were used as supplied. 
Methods  
Extraction of goat fat  
Goat fat was extracted from the adipose tissue of Capra hircus. 
The extraneous materials were manually separated from the 
adipose tissue, which was then rendered by the wet process as 
outlined by Attama and Nkemnele [21]. The adipose tissue was 
grated and subjected to moist heat by boiling with about half its 
weight of water in a water bath for 45 min. The molten fat was 
separated from the aqueous phase after filtering with a muslin 
cloth. The fat was stored in a refrigerator until used. 
Formulation of the solidified reverse micellar solution 
(SRMS) 
According to the procedure outlined by Friedrich and Müller-
Goyman [22], formulation of the solidified reverse micellar solutions 
(SRMS) was prepared with different ratios of goat fat and 
Phospholipid as follows: 1:1, 2:1, 3:1 and 2:3 respectively. All the 
preparations were prepared by melt solidification. 
Formulation of SRMS-based solid lipid microparticles 
(SLMs) 
The reverse micellar microparticles (solid lipid microparticles) were 
prepared to contain: lipid matrix (7.5 % w/w), zidovudine (0, 1, 2, 3, 
5 %w/w), Poloxamer 188 (1 %w/w), thiomersal (0.001 %w/w), 
sorbitol (4 %w/w) and water (to 100 %w/w). The lipid matrix 
consisted of goat fat and Phospholipon® 90H. For each batch, the 
lipid matrix was placed in a stainless steel bowl and heated at 70 
oC until it had completely melted. The drug was poured into the 
melted matrix and mixed. The remaining excipients were weighed 
out appropriately and mixed with the corresponding quantity of 
water. The excipients mixture with water at 70 C was poured into 
the lipid matrix-drug mixture and homogenized at 5000 rpm for 10 
min with Ultra-turrax homogenizer (IKA® 25, Bonn-Bad Godesberg, 
Germany), a creamy emulsion was formed. The hot emulsion was 
then poured into bottle and allowed to recrystallize at room 
temperature for 24 h. The same procedure was repeated for the 
various lipid matrices (1:1, 2:1, 3:1 and 2:3). The dispersions were 
left on the shelf at room temperature to determine their short-term 
stability by monitoring visually the formulations daily for one week. 
At the end of the week, it was observed that only the 1:1 ratio was 
stable while the other ratios were unstable, thus they were 
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discarded. The stable dispersion was then lyophilized to get the 
microparticles. 
Preparation of simulated intestinal fluid (SIF) without 
pancreatin 
This was done by dissolving 6.8 g of monobasic potassium 
sulphate in 250 ml of distilled water. The resulting solution was 
made up to 1000 ml with distilled water. The pH of the solution was 
checked and adjusted to a pH (Suntex TS-2, Taiwan) of 7.2 using 
0.2 N NaOH. 
Preparation of simulated gastric fluid (SGF) without 
pepsin 
A 1.0 g of NaCl was dissolved in 500 ml of distilled water and 7 ml 
of conc. HCl was added. The resulting solution was made up to 
1000 ml with distilled water. The pH of the medium was checked 
with pH (Suntex TS-2, Taiwan) and adjusted to 1.2 with a 2.0 N 
HCl.  
Preparation of calibration plot 
The wavelengths of maximum absorption were determined by 
scanning some samples in the various media used (SIF, SGF, 
ethanol and plasma). From this, the calibration plots of zidovudine 
in these media were obtained and used to calculate the 
corresponding concentrations of drug released from them. A 
calibration curve was obtained at five concentration levels of a 
zidovudine standard solution (0.01- 0.06 mg/ml) showing high 
linearity. 
Release studies 
A sequential drug release in different release media was carried 
out. In each case a 0.5 g of each of the solidified reverse micellar 
microparticles (SRMMs) was placed in a dialysis membrane 
(MWCO 6000-8000 Spectrum Labs, The Netherland) tied at both 
ends and suspended in 250 ml of SGF, placed in a dissolution 
apparatus set to rotate at 100 rpm at a temperature of 37 oC.  At 
intervals of 5 min, 10 min, 20 min, 30 min, 1 h and 2 h respectively, 
5 ml aliquots of the dissolution medium (SGF, pH 1.2) were 
collected and immediately replaced with 5 ml of fresh SGF. After 2 
h, the dissolution medium was changed and replaced with freshly 
prepared SIF (pH 7.2). The drug release in this medium was then 
assessed at hourly intervals for 10 h. Sequel to this the withdrawn 
samples were collected and analyzed using a UV-VIS 
spectrophotometer (UNICO-3102, England) at the appropriate 
predetermined wavelengths. 
 Determination of kinetics and mechanism of release 
The dissolution data for the SLMs were also analyzed to determine 
the in vitro kinetics of release. Four kinetic models including the 
zero-order release equation, first order equation, Higuchi square 
root equation and Korsmeyer equation. 
 
Qt  =  Kot (Zero order equation)      ⁄⁄⁄⁄⁄⁄⁄.               Eqn 1 
InQt = InQo-K1t (First order equation) ⁄⁄⁄⁄⁄⁄⁄..          Eqn 2 
Qt  = Kh.S√t (Higuchi equation based on fickian diffusion)⁄  Eqn 3 
 
Where Q is the amount of drug released in time t, Qo is the initial 
amount of drug in the microparticles, Ko, K1, and Kh are the rate 
constants of zero order, first order and Higuchi rate equations 
respectively. 
Also, the Peppas and Korsenmeyer equation (Power law) was 
used. 
 
Mt ӏܯ∞ ൌKtn ⁄⁄⁄⁄⁄⁄⁄⁄⁄⁄⁄⁄⁄⁄⁄⁄⁄⁄⁄⁄  Eqn 4 
 
Where Mt is the amount of drug released at time t.  M∞ is the 
amount of drug released at time =∞, n is the diffusional exponent 
indicative of the mechanism of drug release, K is the power law 
constant, Mt ӏܯ∞ is the fraction of the drug released; If n ൑ 0.43, a 
Fickian diffusion (case I+); 0.43 ൑ n ൏ 0.89, a non-Fickian 
transport and n ൒ 0.89, a case II transport (zero order, drug 
release mechanism dominates). 
In vivo drug release 
The animal experimental protocols were in accordance with the 
guidelines for conducing animal experiments stipulated by our 
InstitutionÊs Animal Ethics Committee and in compliance with the 
Federation of European Laboratory Animal Science Association 
and the European Community Council Directive of November 24, 
1986 (86/609/EEC) [23]. Fifteen albino Wistar rats weighing 180-
250 g were used for the in vivo test. The rats were divided into five 
groups of three rats per group. They were fed for one week for 
acclimatization. Afterwards, a single dose of 30 mg/kg of 
cyclophosphamide (Oncomide®) was administered to the rats IP 
(intraperitoneally) to induce immune suppression. The immune 
suppressed rats were allowed to starve for 24 h. At the end of this 
period, blood was withdrawn from each of the rats (t=0). 
Subsequently, 1 mg of zidovudine was administered to the rats in 
one group while the equivalent weight of reverse micellar 
preparations that would give 1 mg of zidovudine was administered 
to each of the remaining four groups. After administration, blood 
samples were withdrawn from the retro-orbital plexus of the rats at 
intervals of 1, 3, 5, 8, 12 and 15 h respectively with the aid of 
heparinised capillary tubes. After collection, these samples were 
placed in EDTA bottles and refrigerated. Thereafter, the collected 
blood samples were centrifuged (Abishkar centrifuge, India) at 500 
rpm for 10 min. This plasma was then diluted 50-fold with a plasma 
solution and their absorbance checked using a UV-VIS 
spectrophotometer at a predetermined wavelength of 255 nm. The 
concentration maximum (Cmax), the time to reach the 
concentration maximum (Tmax) and area under curve (AUC) were 
also determined. 
Biodistribution studies 
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The biodistribution of zidovudine from the SRMM to some organs 
of the body was studied using healthy albino rats. Four rats were 
used for the study. A 1 ml solution of pure zidovudine (1 %) was 
administered to two of the rats while the remaining two rats 
received the equivalent dose of zidovudine from B1 batch. Distilled 
water was used to disperse the two drugs. They were then fed 
orally to the rats that had previously been injected with a dose of 
30 mg/kg of cyclophosphamide and allowed to survive on water 
alone for 24 h. After feeding the animals, one from each group was 
sacrificed at intervals of 1 h and 1.5 h respectively. The sacrificed 
animals had their kidneys, livers, spleens and brains harvested. 
The harvested organs were homogenized and the homogenate 
soaked in ethanol for 30 min and then filtered. The filtrates were 
then analysed with a UV-VIS spectrophotometer at the 
predetermined wavelength to determine their absorbance. The 
absorbance values were converted to concentration by reference 
to BeerÊs plot of zidovudine in ethanol.  
Data and statistical analysis  
All experiments were performed at least in triplicates for validity of 
statistical analysis. Results were expressed as mean േ SD. 
ANOVA was performed on the data sets generated using Microsoft 
excel and differences were considered significant for p values ൏ 
0.05. 
Results and Discussion  
A stable polydispersed SLMs was obtained. 
Calibration plots 
Calibration plots indicated linear relationships between absorbance 
and concentration of zidovudine with all the solvents used. The 
following relationships were obtained; Ethanol: A264 = 0.333C (r2 = 
0.9460); SGF pH 1.2: A267 = 0.420C (r2 = 0.9340); SIF pH 7.2: A267 
= 0.486C (r2 = 0.9520); Plasma: A255 = 0.095C (r2 = 0.9910). High 
linearity (r2 > 0.9) was obtained for the calibration plot. With r2 > 0.9 
for all the solvents, proper analysis of AZT could be performed at 
the wavelength of maximum absorption of AZT in these solvents. 
In vitro release studies 
In vitro drug dissolution studies showed that the B1 formulation 
containing 1 % of AZT gave a gradual release of zidovudine. 
Batches B3 and B4 containing 3 % and 5 % of AZT respectively 
had an initial high release which could be adduced to the presence 
of zidovudine on the surface of the microparticles as a result of 
saturation of the lipid matrix. Reddy and Murthy [24] suggested that 
this initial burst release (batch B3 with 16.07 % of drug release 
within 5 min and batch B4 with 36.44 % of drug release within 5 
min) could be as a result of adsorption on the surface of the 
microparticle or precipitation from the superficial lipid matrix. This 
could be advantageous in a formulation since it provides a quantity 
of drug to the body within a short time for therapeutic activity to 
commence before subsequent quantities are delivered gradually to 
maintain this activity. In contrast, the commercial zidovudine tablet 
released almost all of its drug content within 5 min characteristic of 
immediate release. According to Galinsky and Svenson [25], 
prolonged release dosage forms like this solidified reverse micellar 
microparticles have additional advantage of giving a lesser 
fluctuation in blood levels of the drug than with rapidly absorbed 
dosage forms. Particulate drug delivery systems thus perform 
better than tablets in prolongation of drug release. 
Release kinetic studies 
The result of the in vitro release of the different batches was fitted 
into zero order, first order, Higuchi and Korsmeyer models to 
determine the kinetics of release as shown in Table 1. 
 
                                                  Table 1: Kinetic models for the release studies 
Formulation batches of 
microparticle 
zero order 
 
first order Higuchi Korsenmeyer
 r? ܭ௢ r? ܭଵ r? ܭ௛ r? n
B1 in SGF 0.8970 0.054 0.8370 0.007 0.9910 1.166 0.9970 0.538
B1 in SIF 0.8930 0.024 0.9390 0.002 0.9860 1.173 0.9870 0.520
B2 in SGF 0.8340 0.087 0.7860 0.008 0.9660 1.311 0.9590 0.580
B2 in SIF 0.9420 0.025 0.9330 0.002 0.9800 0.599 0.9800 0.466
B3 in SGF 0.7990 0.159 0.7850 0.020 0.9700 0.361 0.9530 0.865
B3 in SIF 0.8740 0.012 0.8710 0.001 0.9310 0.381 0.9820 0.351
B4 in SGF 0.8870 0.144 0.8050 0.010 0.9800 5.971 0.9060 0.882
B4 in SIF 0.9200 0.035 0.8330 0.002 0.9220 1.374 9.9490 0.559
AZT in SGF 0.9000 0.186 0.7350 0.008 0.9920 0.485 0.9700 0.285
AZT in SIF 0.8730 0.034 0.8230 0.002 0.9580 0.283 0.9800 0.288
∗key: r? =regression coefficient, K0= Zero order rate constant, K1= First order rate constant, Kh= Higuchi rate constant, n = Korsenmeyer 
constant, B1 (contained 1 % of AZT in the solidified reverse micellar microparticle), B2 (contained 2 % of AZT in the solidified reverse micellar 
microparticle), B3 (contained 3 % of AZT in the solidified reverse micellar microparticle), B4 (contained 5 % of AZT in the solidified reverse 
micellar microparticle). 
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Analysis of kinetics 
Determining the regression coefficients assessed the fitness of the 
data into various kinetic models of the batches. The rate constants 
for the respective models were calculated from their slopes [26]. 
The statistical analysis showed a high significance difference (p < 
0.05) between the AZT-loaded SLMs and the AZT tablet.   
In vivo release studies 
The B1 batch containing 1 % AZT maintained a gradual release of 
AZT in vivo up to the 15th h while batches B2 and B3 batches 
containing 2 % and 3 % of AZT respectively had optimum release 
at the 8th h before their gradual decline in release while the batch 
B4 containing 5 % of AZT and zidovudine tablet had optimum 
release at the 5th h.  
Pharmacokinetic parameters 
The result of the Cmax, Tmax and AUC for the batches is 
presented in Table 2. 
From the data in Table 2, the Tmax and AUCs for B1 batch 
containing 1 % AZT and zidovuine tablet formulations were almost 
similar. 
 
             Table 2: Pharmacokinetic parameters 
Batch 
Formulations  
Cmax 
(øg/ml) 
Tmax (hrs) AUC (øghr/ml)
B1 116.05 5 1,378.68
B2 124.21 8 1,270.28
B3 128.95 8 1,197.97
B4 138.95 5 1,314.74
AZT tabs 149.47 5 1,402.86
∗key: r? =regression coefficient, K0= Zero order rate constant, K1= 
First order rate constant, 
Kh= Higuchi rate constant, n = Korsenmeyer constant, Cmax = 
maximum concentration 
Tmax = time to reach maximum concentration, AUC = area under 
curve 
Bio-distribution studies 
The bio-distribution profile of AZT tablet and batch B1 containing 1 
% AZT in the various organs were ascertained to determine which 
part of the organs has the highest bioavailability of the drug are 
shown Figs. 1 and 2. The bio-distribution studies of batch B1 
containing 1 % AZT showed a time dependent change in the 
concentrations of the drug in four organs of the body: liver, kidney, 
spleen, and brain, with the drug achieving its highest concentration 
in the liver and least in the brain. 
 
 
 
 
 
Figure 1: Biodistribution studies of zidovudine tablet 
  1 is the biodistribution at 1 h;  1.5 is biodistribution at 1.5 h 
 
 
Figure 2: Biodistribution studies of batch B1 containing 1 % AZT 
 1 is the biodistribution at 1 h;  1.5 is biodistribution at 1.5 h 
 
The results of the calibration plots in different media showed 
linearity between absorbance and concentrations of the zidovudine 
which implies first order kinetics. Analysis of the mechanism of 
drug release from the microparticles showed that the drug release 
followed both diffusion and dissolution mechanisms and Fickian. 
Release kinetic data for all the models are shown in Table 1. Drug 
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release data of conventional tablet was fitted into first order 
equation (r2 = 0.7350 in SGF and 0.8230 in SIF). The result of the 
kinetic analysis of the in vitro release profiles (Table 1) revealed 
that most of the SLM batches predominantly followed the Higuchi 
model of release while B1 and B2 containing 1 % and 2 % of AZT 
respectively both showed the Higuchi and Korsmeyer models of 
release. This implies that zidovudine-loaded SLMs undergo a 
change in surface area as zidovudine dissolved and diffused out of 
the hydrated or solvated SLMs in these batches. Moreover, since 
most of the formulations followed the Higuchi square root model, 
indicating a diffusion controlled release as expected from a 
heterogeneous matrix system [27, 28], it implies that the smooth 
surface of the SRMS-based zidovudine-loaded SLMs have enough 
pores and channels to permit controlled drug release. Therefore, 
the study indicated combined effect of diffusion and erosion 
mechanisms for controlled drug release. The results obtained as 
shown revealed that the best fit release kinetics was obtained with 
the KorsmeyerÊs plot while the Higuchi plot also showed a high 
correlation for the data. This showed some potential for use of this 
preparation as a sustained release form for zidovudine.  In vitro 
drug release studies revealed that batch B1 released its drug 
content gradually while batches B3 and B4 containing 3 % and 5 % 
respectively had an initial burst release before subsequently 
releasing gradually in comparison with the conventional zidovudine 
tablets that released most of its drug content within 5 min.  
The pharmacokinetic parameters determined in vivo (Table 2) 
showed that the Cmax of the drugs increased with increasing drug 
loading. Batch B4 containing 5 % AZT had the highest Cmax of 
138.95 øg/ml. However, the Tmax were at variance with their Cmax. 
Batches B2 and B3 containing 2 % and 3 % AZT respectively had 
similar Tmax of 8 h while the B1 and B4 containing 1 % and 5 % 
respectively had a Tmax of 5 h. The AUCs of the SLMs when 
compared with that of the conventional release tablet showed that 
the formulations had a concentration dependent decrease in their 
relative bioavailabilities of 0.983, 0.905 and 0.854 for batches B1, 
B2 and B3 respectively while that of batch B4 was 0.937. Thus 
drug release from the matrix of the microparticles could be 
described as non-Fickian for batches B1, B2 and B3 batches with 
values within the range: 0.43 ൏ n ൏ 0.85, while drug release from 
the zidovudine tablet was Fickian with an n-value of ൏ 0.43. This 
means that drug was released via a diffusion and dissolution 
mechanism. The difference in the release mechanisms of the 
formulated microparticles and the commercial tablets may be due 
to the tortuosity of the matrix of the microparticles, which thus 
restricted the path of diffusion whereas the simple tablet matrix of 
the commercial tablets made diffusion from its matrix easier and 
faster. In vivo studies also revealed that batch B1containing 1 % 
AZT showed the best properties as it sustained the drug release 
most (up to the 15th h) with drug plasma concentrations within the 
therapeutic range of zidovudine (106.7-1067.0 øg/ml). Other 
batches reached peak plasma concentrations at the 8th h and 
subsequent concentrations were below the therapeutic range of 
zidovudine.  The biodistribution of a molecule in an organ depends 
on a series of pharmacokinetic parameters (physicochemical and 
physiological) such as administration route, dosage form, drug 
liberation rate, diffusion, penetration, permeation, and distribution 
within the body fluids and tissues; biotransformation type, amount, 
and rate; recycling processes; and elimination [29]. Distribution rate 
for each organ tissue is determined by the blood perfusion and the 
facility of passing through vessels and penetrating the cell [30]. 
Diffusion time for different tissues, identification of target tissue, 
and residence time are important information revealed by 
biodistribution studies [30]. Biodistribution studies revealed a time 
dependent concentration of zidovudine in the various organs tested 
(liver, spleen, kidney and brain) with the highest concentration 
occurring in the liver and the least in the brain. A comparison of the 
results obtained for the zidovudine tablet (Fig.1) and the batch B1 
containing 1 % AZT (Fig. 2) revealed greater brain penetration of 
the microparticles possibly due to its higher lipophilicity thus 
enabling it to cross the highly lipophilic blood-brain barrier (BBB). 
Also other organs (liver and kidney) had a greater concentration of 
the drug suggesting greater cell permeation.  In the brain, the 
amount of zidovudine tablet at 1 h and 1.50 h were 24.21 øg and 
17.63 øg while that of batch B1 were 29.27 øg and 29.63 øg 
respectively. In the kidney, the amount of pure zidovudine at 1 h 
and 1.50 h were 30.79 øg and 26.84 øg while that of batch B1were 
40.26 øg and 26.84 øg respectively. In the liver the amount of 
zidovudine tablet at 1 h and 1.50 h were 55.26 øg and 85.79 øg 
while that of batch B1 were 105.53 øg and 84.21 øg respectively. In 
the spleen the amount of pure zidovudine at 1 h and 1.50 h were 
33.16 øg and 36.84 øg while that of batch B1were 29.47 øg and 
30.79 øg respectively. The biodistribution of AZT from batch B1 in 
the kidney, brain, liver were more than the biodistribution of 
zidovudine tablet in those organs. At the spleen, batch B1 has a 
lower biodistribution than the zidovudine tablet. It is reported in the 
literature that more than 30% release of drug within 1 h of 
dissolution indicates the chance of dose dumping. The results 
showed probability of dose dumping from conventional AZT tablets. 
The incorporation of zidovudine into SLM reduced the chances of 
dose dumping. AZT has a very narrow (0.4-4.0 μmol/L) therapeutic 
index [31]. The commercially available conventional tablet 
produces initial high plasma concentration owing to absence of 
release modifiers, which may cause unwanted toxic effects like 
bone marrow depression that sometimes leads to withdrawal of 
drug therapy [32]. The smooth and extended absorption phase 
coupled with maintenance of plasma concentration for longer 
duration after administration in matrix tablets suggests reduced 
chance of dose-dependent side effects of AZT [33].  
The bio-distribution in terms of elimination and retention of the drug 
in different organs vis-à-vis the normal elimination route of the drug 
showed; in the brain the SLM-loaded AZT has higher retention than 
pure AZT; in the kidney and liver the SLM ?loaded AZT even 
though had higher bio-distribution in these organs, the elimination 
was also faster thereby preventing unwanted toxic effect as seen in 
pure AZT and in the spleen the pure AZT had higher bio-
distribution and higher retention. Therefore batch B1 containing 1 
% AZT with highest entrapment efficiency, loading capacity and 
smallest particle size when compared with other batches [34] 
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exhibited the best release profile up to the 15th h and better bio-
distribution than the conventional AZT.  
Conclusion 
Results of the present study demonstrated that SLMs of zidovudine 
could successfully be employed for formulating sustained-release 
dosage forms of AZT. The investigated SLM showed that batch B1 
formulated with 1 % AZT was capable of maintaining constant 
plasma AZT concentration through 15 h and the chance of dose-
dumping associated with conventional AZT tablet will be 
eliminated. This formulation of SLM can be expected to reduce the 
frequency of administration and decrease the dose-dependent side 
effects associated with repeated administration of conventional 
AZT tablets as a result of very short half due to first-pass 
metabolism and fast renal excretion and variable bio-distribution; 
the gradual release of the SLMs with concentrations within the 
therapeutic range of AZT as opposed to the initial burst release of 
the conventional release tablets would be advantageous in 
reducing the dose-dependent side effects associated with repeated 
administration of conventional AZT tablets.  The biodistribution 
studies of the SLMs showed ability to distribute to the major organs 
of the body achieving concentrations that were slightly higher than 
that of conventional tablets, this could enhance efficacy of the drug.  
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